DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening and Pharmacological Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) comprises 2,320 clinically approved bioactive compounds, supporting drug repositioning and target identification in high-throughput and high-content screening workflows (APExBIO). All compounds are pre-dissolved at 10 mM in DMSO and validated for stability at -20°C (12 months) and -80°C (24 months). Mechanistic diversity includes enzyme inhibitors, receptor agonists/antagonists, and signal pathway modulators. The library enables identification of novel agonists and antagonists for complex targets, such as GPCRs and TAS2Rs (Fierro et al., 2023). Results from recent studies demonstrate acceleration of target deconvolution and drug repositioning pipelines in oncology and neurodegeneration.

Biological Rationale

Drug discovery research often relies on screening collections of well-characterized compounds to identify new therapeutic candidates and investigate biological mechanisms. FDA-approved drugs, collectively representing decades of clinical validation, are prime candidates for repurposing and mechanistic pathway analysis (Fierro et al., 2023). G-protein-coupled receptors (GPCRs) constitute the largest family of membrane proteins in humans, with approximately 800 members. Over 450 FDA-approved drugs target GPCRs, accounting for nearly one third of all approved drugs as of December 2022 (Fierro et al., 2023). Mechanism-driven compound libraries—such as the DiscoveryProbe™ FDA-approved Drug Library—enable researchers to systematically interrogate cellular pathways, signaling networks, and disease models. The inclusion of diverse pharmacological classes (e.g., enzyme inhibitors, ion channel modulators) extends utility across oncology, neurodegenerative diseases, and rare disease research (Annexin-v-pe.com).

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library contains compounds with a broad range of mechanisms, including:

• Receptor Agonists/Antagonists: Compounds modulate GPCRs, nuclear receptors, or ion channels, affecting signal transduction (Fierro et al., 2023).
• Enzyme Inhibitors: Target kinases, phosphatases, proteases, and other enzymes, regulating metabolic and signaling pathways.
• Signal Pathway Regulators: Modulate pathways such as mTOR, MAPK, and PI3K, relevant to cell growth, apoptosis, and differentiation (MOG35-55.com).
• Ion Channel Modulators: Influence neuronal excitability and cardiac function.

Representative drugs include doxorubicin (DNA intercalator, anticancer), metformin (AMPK activator, antidiabetic), and atorvastatin (HMG-CoA reductase inhibitor, lipid-lowering agent). The diversity of mechanisms underlies the library’s value for screening against complex biological targets and pathways.

Evidence & Benchmarks

• Iterative screening of an FDA-approved drug library enabled the identification of 10 new TAS2R14 antagonists and 200 new agonists, illustrating the power of repurposing screens for GPCR research (Fierro et al., 2023).
• 9% of ~1,800 pharmaceutical drugs tested activated TAS2R14, with nine compounds active at sub-micromolar concentrations, demonstrating the prevalence of off-target GPCR activity among approved drugs (Fierro et al., 2023).
• The DiscoveryProbe™ FDA-approved Drug Library supports robust high-throughput screening (HTS) and high-content screening (HCS) workflows, with pre-dissolved 10 mM DMSO solutions ensuring precise, reproducible delivery (APExBIO product page).
• Stability benchmarks: All compounds remain stable for 12 months at -20°C and up to 24 months at -80°C in DMSO format (APExBIO).
• Applications in oncology and neurodegenerative disease research have been documented, accelerating the identification of pharmacological targets and repositioning opportunities (Annexin-v-pe.com; N6-methyl.com).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is designed for multiple research applications:

• High-throughput screening for novel modulators of GPCRs, kinases, and other druggable targets.
• Drug repositioning to uncover new indications for existing drugs.
• Pharmacological target identification via phenotypic and mechanistic assays.
• Signal pathway analysis in disease models, including cancer and neurodegenerative diseases (N6-methyl.com).

This article extends prior coverage by focusing on the iterative experimental-computational framework that enabled novel TAS2R14 ligand discovery, as described in Fierro et al. (2023), whereas earlier articles such as this high-throughput screening overview emphasize library logistics and translational workflows.

Common Pitfalls or Misconceptions

• The library is not suitable for discovery of entirely novel chemical scaffolds, as all compounds are already clinically approved.
• Off-target effects are common; secondary assays are essential to confirm on-target activity.
• Not all disease models are equally responsive to small-molecule modulation; some require genetic or biologic interventions.
• Compound concentrations above 10 mM may precipitate or cause DMSO-related cytotoxicity.
• Stability claims assume continuous storage at -20°C or below; repeated freeze/thaw cycles can compromise compound integrity.

Workflow Integration & Parameters

The DiscoveryProbe™ library is formatted for seamless integration into high-throughput and high-content screening pipelines. Key workflow parameters include:

• Pre-dissolved 10 mM DMSO solutions in 96-well microplates, deep-well plates, or 2D-barcoded tubes.
• Screening platforms: Compatible with automated liquid handlers and robotics.
• Storage: 12 months at -20°C or 24 months at -80°C; avoid repeated freeze/thaw cycles.
• Shipping: Blue ice for evaluation samples; room temperature or blue ice for other sizes, as requested.
• Typical working concentrations: 0.1–10 μM in cell-based or biochemical assays, depending on endpoint sensitivity.
• Quality control: Each batch undergoes identity and concentration verification by LC-MS and NMR, per APExBIO specifications (APExBIO).

For advanced integration strategies and live-cell assay workflows, readers are referred to this translational acceleration roadmap, which details mTORC1 pathway modulation and real-time screening technologies not covered here.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO is a validated, versatile resource for high-throughput and high-content screening, drug repositioning, and target identification. Its extensive coverage of clinically approved drugs, paired with robust compound stability and mechanistic diversity, positions it as an essential tool for translational research. Recent peer-reviewed studies underscore its capacity to reveal novel pharmacological activities for existing drugs, particularly in GPCR and TAS2R research (Fierro et al., 2023). Researchers are encouraged to leverage this library in conjunction with orthogonal validation strategies and emerging assay technologies to maximize discovery potential. For further details and ordering, please visit the DiscoveryProbe™ FDA-approved Drug Library product page.